Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
Part of paid clinical trials in Miami, Florida.
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Study ID
- NCT03997643
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Radiotherapy to all dissected areas — RADIATIONPost operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
- Omit radiation to pN0 neck — RADIATIONpost operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
Study Details
The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.
Key Dates
- Start date
- Sep 6, 2019
- Status verified
- Aug 2023
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Standard RadiotherapyRadiotherapy to all dissected areas
- Experimental: Radiotherapy to smaller treatment areaOmit radiation to pN0 neck
Primary Outcome Measure
Regional failure in the pN0 hemi-neck (s) [ Time Frame: Baseline to 5 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Miami Cancer Institute | Miami | Florida | 33143 |
Find similar trials in Miami, FL
By condition
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPHASE1 · Recruiting · Memgen, Inc. · Tampa, Florida
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruiting · Adela, Inc · Duarte, California
- PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR SurvivorsRecruiting · University of Miami · Miami, Florida